Genetic variants predicting aerobic capacity response to training are also associated with skeletal muscle oxidative capacity in moderate-to-severe COPD. by Adami, A et al.
PG SNPs
Genetic variants predicting aerobic capacity response to training are also
associated with skeletal muscle oxidative capacity in moderate-to-severe
COPD
X Alessandra Adami,1,2 Brian D. Hobbs,3,4 Merry-Lynn N. McDonald,5 Richard Casaburi,1 and
X Harry B. Rossiter;1,6 for the COPDGene Investigators
1Rehabilitation Clinical Trials Center, Division of Pulmonary and Critical Care, Physiology and Medicine, Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California; 2Department of Kinesiology,
University of Rhode Island, Kingston, Rhode Island; 3Channing Division of Network Medicine, Brigham and Women’s
Hospital, Boston, Massachusetts; 4Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital,
Boston, Massachusetts; 5Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham,
Birmingham, Alabama; and 6Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom
Submitted 20 December 2017; accepted in final form 20 May 2018
Adami A, Hobbs BD, McDonald MN, Casaburi R, Rossiter HB,
for the COPDGene Investigators. Genetic variants predicting aero-
bic capacity response to training are also associated with skeletal
muscle oxidative capacity in moderate-to-severe COPD. Physiol
Genomics 50: 688–690, 2018. First published May 25, 2018; doi:
10.1152/physiolgenomics.00140.2017.—Muscle oxidative capacity is
a major determinant of maximum oxygen uptake (V˙ O2max). V˙ O2max
predicts survival in humans. Muscle oxidative capacity is low in
chronic obstructive pulmonary disease (COPD) and can be assessed
from the muscle oxygen consumption recovery rate constant (k) by
near-infrared spectroscopy. We hypothesized that 11 SNPs, previ-
ously associated with the increase in V˙ O2max following exercise
training, would correlate with k in 152 non-Hispanic White and
African American smokers with and without COPD. Associations
were adjusted for age, weight, FEV1% predicted, steps/day, and
principal components of genetic ancestry. No SNPs were significantly
associated with k. rs2792022 within BTAF1 (  0.130, P  0.053)
and rs24575771 within SLC22A3 (  0.106, P  0.058) approached
nominal significance. Case-control stratification identified three SNPs
nominally associated with k in moderate-to-severe COPD (rs6481619
within SVIL   0.152, P  0.013; BTAF1   0.196, P  0.046;
rs7386139 within DEPTOR   0.159, P  0.047). These data
support further study of the genomic contributions to skeletal muscle
dysfunction in COPD.
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BACKGROUND/MOTIVATION FOR THE STUDY
Low maximum oxygen uptake (V˙ O2max) holds stronger
mortality risk than other established variables such as smoking,
obesity or diabetes. Positive adaptation in V˙ O2max following
increased physical activity is a key inherited trait promoting
survival. Plasticity in skeletal muscle oxidative capacity plays
a major role in mediating this response (3). The HERITAGE
study of 99 families that completed a 20 wk endurance training
program identified ~50% heritability of V˙ O2max plasticity (2).
Later, Timmons et al. (5) identified in muscle biopsies an
mRNA expression-based molecular classifier of 29 genes pre-
dicting the training response and which were associated with
11 single nucleotide polymorphisms (SNPs) in the HERITAGE
cohort. Approximately half of the genetic variance for V˙ O2max
gained by exercise training was accounted for by these 11
SNPs.
Chronic obstructive pulmonary disease (COPD) is charac-
terized by dyspnea, chronic inactivity, and negative muscle
adaptations: major among these is loss of muscle oxidative
capacity. Detrimental peripheral adaptations increase ventila-
tory demand during activities of daily living and are associated
with reduced quality of life, morbidity, and mortality in COPD.
While genomic and epigenomic variations in oxidative phos-
phorylation genes have been studied widely in chronic dis-
eases, genetic association studies to explain low muscle oxi-
dative capacity in humans have not. We therefore determined
whether the 11 SNPs associated with muscle plasticity in
healthy Caucasians were associated with variability in muscle
oxidative capacity in non-Hispanic White (NHW) and African
American (AA) smokers with and without COPD. Identifying
new genetic loci associated muscle adaptations in COPD could
potentially identify patients who may benefit most from pul-
monary rehabilitation.
PHENOTYPE
Cohort details. Participants were NHW (n  84) and AA
(n 68) aged 45–80 yr with a10 pack-year smoking history
from the COPDGene population cohort study (4). Exclusion
criteria included non-COPD respiratory disorders, known or
suspected lung cancer or other cancer, lung volume reduction,
pregnancy, radiation therapy to the chest, chest or abdominal
surgery (past 3 mo), heart attack (past 3 mo), hospitalization
(past month). The 243 participants gave written informed
consent to participate in the COPDGene Muscle Health ancil-
lary study at LABioMed/Harbor-UCLA (Appendix 1, Supple-
mental Fig. S1). (The online version of this article contains
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supplemental material.) The primary trait of gastrocnemius
oxidative capacity was determined from the muscle V˙ O2 re-
covery rate constant (k) using near-infrared spectroscopy (1).
Physical activity (steps/day) was assessed during the fol-
lowing 7 days by triaxial accelerometry (DynaPort Move-
Monitor, McRoberts). Complete data from 84 COPD (66 
9 yr) and 68 smokers with normal spirometry (61  9 yr)
were used for final analyses (Appendix 2, Supplemental
Table S1). Additional details are provided in Appendix 3.
Type of study. Candidate SNP study.
Details of the SNP(s) studied. Candidate SNPs were identi-
fied from Timmons et al. (5) representing 11 different genetic
loci (see Appendix 3, Supplemental Table S1 for complete
list). Genotyping for the COPDGene study was performed on the
Illumina Human Omni-1 Quad array with imputation using the
Haplotype Reference Consortium on the Michigan Imputation
Server. Quality control details of the COPDGene genotyping data
are given in Appendix 2, Supplemental Table S2. Four of the
investigated SNPs were imputed: rs3770991 within NRP2;
rs4257918 within CPVL; rs2251375 within H19; rs1546570
within DIS3L (Appendix 3, Supplemental Table S1). SNPs were
annotated using wANNOVAR (see Appendix 3).
Analysis model. COPD was defined as forced expiratory
volume in 1 s/forced vital capacity (FEV1/FVC) 0.7, while
controls had FEV1/FVC  0.7. In a secondary analysis, mod-
erate-to-severe COPD cases were defined as FEV1/FVC  0.7
and FEV1  80% predicted. Student’s t-tests between controls
and COPD were used to identify differences in k (positively
dependent upon muscle oxidative capacity) or habitual physi-
cal activity from number of steps/day. Linear regression with
an additive genetic model was performed to identify associa-
tion of k with each of the 11 SNPs, adjusting for age, weight,
FEV1% predicted, steps/day, and principal components of
genetic ancestry using PLINK2.0. Stratified models in moder-
ate-to-severe COPD cases and controls were also evaluated for
association with k. NHW and AA individuals were analyzed
separately; results were then combined in a fixed-effects meta-
analysis in METAL, resulting in a total sample size of 152 in
the fully adjusted model. Bonferroni-corrected significance
was accepted at P  0.0045, and nominal significance was
defined as P  0.05.
RESULTS
COPD patients had lower muscle k than controls (mean SD
in all COPD vs controls, 1.26 0.37 min1 vs. 1.60 0.44
min1, P 0.0001). Steps/day did not differ between COPD and
controls (5,740 4,726 vs. 6,509 3,294; P 0.24) (Appendix
1, Supplemental Fig. S2).
No SNPs were significantly associated with k in meta-
analysis (Appendix 2, Supplemental Table S3). rs2792022
within BTAF1 [effect allele frequency (EAF)  0.819,  
0.130, P  0.053] and rs24575771 within SLC22A3 (EAF 
0.352,   0.106, P  0.058) tended toward nominal sig-
nificance. Subsequent analysis, stratified by disease state, identi-
fied three SNPs nominally associated with k in moderate-to-severe
COPD only (rs6481619 within SVIL, EAF  0.746,   0.152,
P  0.013; BTAF1, EAF  0.798,   0.196, P  0.046,
I2 41.6; Het_P  0.191; rs7386139 within DEPTOR,
EAF 0.219,  0.159, P 0.047; Appendix 2, Supplemental
Tables S4 and S5). Forest plots stratified by genetic ancestry and
disease state are in Appendix 3, Supplemental Figures S1–S3.
Two other SNPs tended toward nominal significance in COPD
(P  0.1; Appendix 2, Supplemental Table S5). Results of all
models stratified by genetic ancestry are in Appendix 3, Supple-
mental Tables S2–S4.
INTERPRETATION
This study of 152 smokers is the first to associate SNPs
[from candidates identified by Timmons et al. (5)] with muscle
oxidative capacity in humans. Nominal association of k in
moderate-to-severe COPD patients with a SNP intrinsic to
DEPTOR is of particular interest as this gene is involved with
molecular, metabolic, and contractile properties characteristic
of glycolytic muscle. As our models adjusted for pulmonary
function (FEV1) and physical activity (daily steps), the finding
of nominally associated SNPs with k in moderate-to-severe
COPD subjects only, and not in controls, suggests an interac-
tion of these variants with some as-yet-unidentified aspect of
COPD. Validation of these candidates may identify new risk
factors for symptoms and/or poor outcomes in COPD and other
lung diseases where peripheral deconditioning and low muscle
oxidative capacity contributes significantly to disease burden.
Given that pulmonary rehabilitation is the most beneficial
treatment for severe COPD, these SNPs may provide a means
of personalizing COPD therapy. These data strengthen the
rationale for a larger study to identify potential contributions of
genetic variants to low muscle oxidative capacity in COPD
patients.
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